Literature DB >> 33515198

CYP2C9 inhibits the invasion and migration of esophageal squamous cell carcinoma via downregulation of HDAC.

Zhenzhen Jiang1, Xiaoli Zheng1, Weijia Wang2, Liqing Qiu1, Lingrong Yang1, Mingfeng Jiang1, Yuhui Hua3.   

Abstract

Cytochrome P450 2C9 (CYP2C9) is involved in the metabolism of cancer drugs and exogenous carcinogens. In our study, CYP2C9 was downregulated in multiple cohorts of human esophageal squamous cell carcinoma (ESCC). Until now, its role and epigenetic regulation of CYP2C9 repression in ESCC remain poorly understood. CYP2C9 repression in collected ESCC patient tumor tissues was demonstrated by RT-qPCR and Western blot. The histone acetylation level was carried out by the treatment of histone deacetylase inhibitor TSA and RNA interference. Epigenetic analysis revealed that the increased expression of CYP2C9 in KYSE-150 and TE1 cells was characterized by inhibition of HDAC8 and HDAC1, respectively. TSA decreased the levels of HDAC occupancy around CYP2C9 promoter region greatly. Overexpression of CYP2C9 reduced the invasion and migration of ESCC cells.

Entities:  

Keywords:  CYP2C9; ESCC; HDAC; Histone acetylation

Year:  2021        PMID: 33515198     DOI: 10.1007/s11010-021-04050-3

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  1 in total

1.  Whole-brain radiotherapy with and without concurrent erlotinib in NSCLC with brain metastases: a multicenter, open-label, randomized, controlled phase III trial.

Authors:  Zhenzhou Yang; Yan Zhang; Rongqing Li; Abulimiti Yisikandaer; Biyong Ren; Jianguo Sun; Jianjun Li; Long Chen; Ren Zhao; Juying Zhang; Xuefeng Xia; Zhongxing Liao; David P Carbone
Journal:  Neuro Oncol       Date:  2021-06-01       Impact factor: 12.300

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.